Efficacy and safety of piperacillin/tazobactam versus biapenem in late elderly patients with nursing- and healthcare-associated pneumonia

Journal of Infection and Chemotherapy

Volumn 19, Issue 5, 2013, Pages 909-915

  Karino, Fumi ^a   Miura, Kiyotaka ^a   Fuchita, Hiroshi ^a   Koba, Naoya ^a   Nishikawa, Emiko ^a   Hotta, Takamasa ^a   Okimoto, Tamio ^a   Iwamoto, Shinichi ^a   Tsubata, Yukari ^a   Tada, Mitsuhiro ^a   Hamaguchi, Shunichi ^a   Honda, Takeshi ^a   Ohe, Miki ^a   Sutani, Akihisa ^a   Kuraki, Takashige ^a   Takeyama, Hiroyasu ^a   Isobe, Takeshi ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Biapenem; Efficacy; Late elderly patients; Nursing associated and healthcare associated pneumonia; Piperacillin tazobactam; Safety

Indexed keywords

BIAPENEM; PIPERACILLIN PLUS TAZOBACTAM;

AGED; ARTICLE; BACTERIUM DETECTION; BODY TEMPERATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE ASSOCIATED PNEUMONIA; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; OUTCOME ASSESSMENT; PSEUDOMEMBRANOUS COLITIS; RETROSPECTIVE STUDY; SCORING SYSTEM; SPUTUM CULTURE; THORAX RADIOGRAPHY; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CROSS INFECTION; FEMALE; HOSPITALIZATION; HUMANS; MALE; PENICILLANIC ACID; PIPERACILLIN; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; SPUTUM; THIENAMYCINS;

EID: 84885953697     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-013-0605-x     Document Type: Article

References (22)

1. Ministry of Health, Labour and Welfare. Specified Report of Vital Statistics in fiscal year 2007.
2. The Committee for the Japanese Respiratory Society guidelines in management of nursing and healthcare-associated pneumonia. The Japanese Respiratory Society guideline for the management of nursing and healthcare-associated pneumonia. Jpn Respir Soc. 2011;1-39.
3. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
4. Kozawa O, Uematsu T, Matsuno H, Niwa M, Takiguchi Y, Matsumoto S, et al. Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects. Antimicrob Agents Chemother. 1998;42:1433-6.
5. Karino F, Deguchi N, Kanda H, Ohe M, Kondo K, Tada M, et al. Evaluation of the efficacy and safety of biapenem against pneumonia in the elderly and a study on its pharmacokinetics. J Infect Chemother. 2013;19:98-102.
6. Lepper PM, Grusa E, Reichl H, Högel J, Trautmann M. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2002;46:2920-5.
7. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr T, Andersen MH, et al. Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. BMJ Open. 2012;. doi: 10.1136/bmjopen-2011-000635.
8. Gilbert DN, Moellering RC, Eliopoulos GM, Chambers HF, Saag MS. The Sanford guide to antimicrobial therapy 2011, 41th ed. Antimicrobial therapy. Sperryville, VA; 2011. p. 192.
9. Saito A, Miki F, Oizumi K, Rikitomi N, Watanabe A, Koga H, et al. Clinical evaluation methods for new antimicrobial agents to treat respiratory infections: report of the Committee for the Respiratory System, Japan Society of Chemotherapy. J Infect Chemother. 1999;5:110-23.
10. Ministry of Health, Labour and Welfare. Classification criteria of severity of adverse drug reactions 2003;100-110.
11. Miyashita N, Matsushima T, Oka M. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med. 2006;45:419-28.
12. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50.
13. Ito I, Kadowaki S, Tanabe N, Haruna A, Kase M, Yasutomo Y, et al. Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: comparison with imipenem/cilastatin. Pulm Pharmacol Ther. 2010;23:403-10.
14. Yamamoto Y, Izumikawa K, Morinaga Y, Nakamura S, Kurihara S, Imamura Y, et al. Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan. J Infect Chemother 2013. doi 10.1007/s10156-013-0552-6.
15. Tsukada H, Sakai K, Cho H, Kimura Y, Tetsuka T, Nakajima H, et al. Retrospective investigation of the clinical effects of tazobactam/piperacillin and sulbactam/ampicillin on aspiration pneumonia caused by Klebsiella pneumoniae. J Infect Chemother. 2012;18:715-21.
16. Réa-Neto A, Niederman M, Lobo SM, Schroeder E, Lee M, Kaniga K, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin. 2008;24:2113-2126.
17. Schmitt DV, Leitner E, Welte T, Lode H. Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia: a double blind prospective multicentre study. Infection. 2006;34:127-34.
18. Joshi M, Metzler M, McCarthy M, Olvey S, Kassira W, Cooper A. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respir Med. 2006;100:1554-65.
19. Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother. 1998;42:2966-72.
20. Landersdorfer CB, Kirkpatrick CMJ, Kinzig M, Bulitta JB, Holzgrabe U, Sörgel F. Inhibition of flucloxacillin tubular renal secretion by piperacillin. Br J Clin Pharmacol. 2008;66:648-59.
21. Ishida T, Tachibana H, Ito A, Yoshioka H, Arita M, Hashimoto T. Clinical characteristics of nursing and healthcare-associated pneumonia: a Japanese variant of healthcare-associated pneumonia. Intern Med. 2012;51:2537-44.
22. Miyashita N, Kawai Y, Akaike H, Ouchi K, Hayashi T, Kurihara T, et al. Clinical features and the role of atypical pathogens in nursing and healthcare-associated pneumonia (NHCAP): differences between a teaching university hospital and a community hospital. Intern Med. 2012;51:585-94.